Carboplatin (NSC 241240)

Name: Carboplatin (NSC 241240)
Brand: Selleck Chemicals
SKU: S1215
Rating: 5 (75 reviews)

For research use only.

Catalog No.S1215 Synonyms: JM-8, CBDCA

75 publications

Carboplatin (NSC 241240) Chemical Structure

CAS No. 41575-94-4

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Selleck's Carboplatin (NSC 241240) has been cited by 75 publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Cancer Cell, 2013, 24(5):617-30

PubMed: 24229709 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3636

PubMed: 34140467 ( click the link to review the publication )

Cell Rep, 2021, 34(10):108814

PubMed: 33691114 ( click the link to review the publication )

Cancer Lett, 2021, 504:137-145

PubMed: 33571541 ( click the link to review the publication )

Cancer Lett, 2021, 520:267-280

PubMed: 34375710 ( click the link to review the publication )

J Pathol, 2021, 10.1002/path.5652

PubMed: 33620092 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1442

PubMed: 33810010 ( click the link to review the publication )

Cancers (Basel), 2021, 13(5)956

PubMed: 33668819 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab424

PubMed: 34120183 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(10)5384

PubMed: 34065402 ( click the link to review the publication )

Eur J Pharmacol, 2021, 895:173887

PubMed: 33482182 ( click the link to review the publication )

SLAS Discov, 2021, 24725552211020668

PubMed: 34111999 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Sci Adv, 2021, 7(6)eabc8346

PubMed: 33536206 ( click the link to review the publication )

Nat Commun, 2020, 24;11(1):1975

PubMed: 32332851 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):2573

PubMed: 32444794 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(4):e11177

PubMed: 32115889 ( click the link to review the publication )

Cancer Res, 2020, 80(4):890-900

PubMed: 31857293 ( click the link to review the publication )

Cancer Lett, 2020, 472:59-69

PubMed: 31866467 ( click the link to review the publication )

Sci Signal, 2020, 13(619)

PubMed: 32071169 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):975

PubMed: 33184273 ( click the link to review the publication )

Br J Cancer, 2020, 3

PubMed: 32242101 ( click the link to review the publication )

J Clin Med, 2020, 28;9(4) pii: E924

PubMed: 32231055 ( click the link to review the publication )
Cells, 2020, 9(6):E1474

PubMed: 32560232 ( click the link to review the publication )

Mol Cancer Ther, 2020, 25;molcanther.1021.2019

PubMed: 32451331 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

J Biomed Sci, 2020, 27(1):42

PubMed: 32169072 ( click the link to review the publication )

J Gynecol Oncol, 2020, 31(3):e28

PubMed: 31912682 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Cell Oncol, 2020, 7(6):1805094

PubMed: 33235906 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30647-9

PubMed: 33278498 ( click the link to review the publication )

Neuropathol Appl Neurobiol, 2020, 10.1111/nan.12641

PubMed: 32603552 ( click the link to review the publication )

Front Microbiol, 2020, 10:2936

PubMed: 32038511 ( click the link to review the publication )

Oncotarget, 2020, 11(40):3660-3674

PubMed: 33088426 ( click the link to review the publication )

Oncotarget, 2020, 17;11(11):969-981

PubMed: 32215185 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(19):5925-5936

PubMed: 31300448 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):199

PubMed: 31362778 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):714

PubMed: 31558709 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

Mol Hum Reprod, 2019, 25(10):601-613

PubMed: 31393565 ( click the link to review the publication )

Biol Res, 2019, 52(1):13

PubMed: 30894224 ( click the link to review the publication )

Oncotarget, 2019, 10(65):6981-6996

PubMed: 31857852 ( click the link to review the publication )

Oncotarget, 2019, 10(49):5011-5019

PubMed: 31489111 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6691-6712

PubMed: 31803363 ( click the link to review the publication )

Mol Ther, 2018,

PubMed: 29724685 ( click the link to review the publication )
Cancer Lett, 2018, 436:75-86

PubMed: 30120964 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Neoplasia, 2018, 20(8):826-837

PubMed: 30015158 ( click the link to review the publication )

SLAS Discov, 2018, 23(7):687-696

PubMed: 29865911 ( click the link to review the publication )

Oncol Lett, 2018, 16(6):7131-7138

PubMed: 30546448 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28456-28473

PubMed: 29983873 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(6):1397-1406

PubMed: 27663600 ( click the link to review the publication )

Cell Rep, 2017, 19(1):101-113

PubMed: 28380350 ( click the link to review the publication )

Breast Cancer Res, 2017, 19(1):93

PubMed: 28810913 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28060758 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51733-51747

PubMed: 28881682 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2017, 8:317-329

PubMed: 28918032 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28086243 ( click the link to review the publication )

Sci Rep, 2017, 7:42319

PubMed: 28176879 ( click the link to review the publication )

Nat Commun, 2016, 7:12351

PubMed: 27484502 ( click the link to review the publication )

Nat Commun, 2016, 7:12088

PubMed: 27357444 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(17):E2373-82

PubMed: 27071093 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-16-0004

PubMed: 27256375 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71696-71702

PubMed: 27765934 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26047477 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27923-37

PubMed: 26314846 ( click the link to review the publication )
Clin Cancer Res, 2014, 20(14):3849-61

PubMed: 24850841 ( click the link to review the publication )

University of South Florida, 2014, /

PubMed: / ( click the link to review the publication )

PLoS One, 2013, 8(9):e72637

PubMed: 24039787 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description

Features

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[6]

Targets

DNA synthesis ^[1]
(A2780, SKOV-3, IGROV-1, HX62 cells)

In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. ^[1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Tca8113/ut	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmyMVI26oDLzszN	NXnUZYxzPzJiaB?=		MkHobY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|N{GwOUc,OjZzM{exNFU9N2F-
Tca8113/CBP	MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHizOYwzNTJ34pEJ{txO	M2XTdlczKGh?		NVjFPGM2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	M4\xe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NVA2Lz5{NkGzO\|ExPTxxYU6=
Tca8113/PYM	NH3uc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVuyMVI26oDLzszN	NXzoU\|BtPzJiaB?=		MUXpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6	MlrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{exNFUoRjJ4MUO3NVA2RC:jPh?=
SKOV3	NX;kNJMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XUelYxKG2pL33s	MXGxMVUh\A>?		NYXENmw4cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?=	NILab5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO\|A1Oyd-Mk[xN\|cxPDN:L3G+
SKOV3	NVnTW3FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVywMVQh\|rypL33s	MlTnNlQwPDhxN{KgbC=>		MX7pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6	NHTqOJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGyOVI4Oyd-Mk[xNlUzPzN:L3G+
SKOV3	M{j4O2Fxd3C2b4Ppd{BCe3OjeR?=	M4rxbFIh\|rypL33s	MWq0PEBp		MVnpcoR2[2W\|IHHwc5B1d3Orcx?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF{NUK3N{c,OjZzMkWyO\|M9N2F-
OSA	MmfpR4xwdm:pZX7pZ{BCe3OjeR?=	M1TjSVIvPS93IN88US=>			NVTL[oZwemW\|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?=	Mn7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzMUC2NlAoRjJ4MUGwOlIxRC:jPh?=
A549	NGm1eXZHfWO2aX;uJGF{e2G7	NUO4flc5OC9{NT:1NEDPxE1?	Mmm5NlQhcA>?		NVPQT\|Zv\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=>	NFTkPY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO\|MyPyd-MkW5NVc{OTd:L3G+
H1975	MXjGeYN1cW:wIFHzd4F6	MnzFNE8zPS93MDFOwG0>	MWeyOEBp		NVK0[m5[\G:5boLl[5Vt[XSnczDtbXIuOjB3IHX4dJJme3Orb39CpC=>	MnG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N\|E4RC:jPh?=
A549	M3r5b2Z2[3Srb36gRZN{[Xl?	NX;kemlGOC9{NT:1NEDPxE1?	MUGyOEBp		MXj1dJJm\3WuYYTld{BucVJvMkG4JIV5eHKnc4Ppc44>	MorMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N\|E4RC:jPh?=
H1975	NIXIS21HfWO2aX;uJGF{e2G7	NFvTPFcxNzJ3L{WwJO69VQ>?	NGrCN2YzPCCq		NV[zdWh[fXC{ZXf1cIF1\XNibXnSMVIyQCCneIDy[ZN{cW:w	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{OxO{c,OjV7MUezNVc9N2F-
A549	NVTZRnpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;Wblc6OjVizszN	NF;tOFgzPCCq		MVnpcohq[mm2czDj[YxtKGe{b4f0bC=>	NIPB[W49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxO\|MyPyd-MkW5NVc{OTd:L3G+
H1975	M4DSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3e3WFI2KM7:TR?=	NVzOcWZUOjRiaB?=		MlvGbY5pcWKrdIOgZ4VtdCCpcn;3eIg>	MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUezNVcoRjJ3OUG3N\|E4RC:jPh?=
MDA-MB-231	MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37xT\|AuOjJyIN88[{9udA>?	MlXsO\|IhcA>?		NVTx[oMyUUN3MNMgQUA5PiEQvF2=	NX[xelI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|c3QTFpPkK1PFM4PjlzPD;hQi=>
T47D	MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUSwMVIzOCEQvHevcYw>	MmntO\|IhcA>?		NED5Zm9KSzVywrC9JFQ5NjlizszN	M1TabVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO3OlkyLz5{NUizO\|Y6OTxxYU6=
LCTCC	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ntdmlEPTB;Mz645qCKyrWP	NGTHbFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3N\|E3Pyd-MkW3O\|MyPjd:L3G+
MCTCC	NH\5TIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFT2TYJKSzVyPUKuPQKBkcL3TR?=	Mnn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MegTCC	NIrSeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrtWoZMUUN3ME20MlHjiIoEtV2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5M{G2O{c,OjV5N{OxOlc9N2F-
MonoTCC	M{PDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGG3RYxKSzVyPUWuOwKBkcL3TR?=	MmO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{OxOlcoRjJ3N{ezNVY4RC:jPh?=
MCF7	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3H6XFIxKM7:TR?=	MkHuO\|IhcA>?		MkX6bY5lfWOnczDj[YxtKGSnYYToJI9nKEiSMd8yMYRmeGyndHXkJG1ETjdiY3XscJM>	NUXPNVlnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OlkxOjVpPkK1O\|Y6ODJ3PD;hQi=>
A-549	M2Ho[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVSwMlUh\|ryP	NVjC[G9pOjRiaB?=	NHfGTGZFVVORwrC=	MVPpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7	MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
A-549	M2P6NGFxd3C2b4Ppd{BCe3OjeR?=	MlfLNE42KM7:TR?=	M1XhTVQ5KGh?	NVvCPWJUTE2VT9Mg	NVTBTGdUe2ixd4Og[YFzdHliYYDvdJRwe2m\|IH\lZZR2emW\|IHnuZ4x2\GmwZzDicIVj[mmwZzDhcoQh[2i{b33heIlvKGOxbnTlcpNifGmxbh?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd3NU[5NEc,OjV5NUW2PVA9N2F-
A-549	M{f0TGZ2[3Srb36gRZN{[Xl?	NX3r[IdjOC53IN88US=>	M4frd\|Q5KGh?	NXz6NXVnTE2VT9Mg	M2HucpNpd3e\|IHHi[ZJz[W62IH3pZ5JwfHWkdXzlJIRqe3K3cITpc44>	M2PkUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{W1OlkxLz5{NUe1OVY6ODxxYU6=
A-549	MUXGeYN1cW:wIFHzd4F6	MoLhNE42KM7:TR?=	NX;WUJREPDhiaB?=	NUXhSY12TE2VT9Mg	MUXpcohq[mm2czDv[kBk\WyuIH3p[5JifGmxbtMg	MlrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NUW2PVAoRjJ3N{W1OlkxRC:jPh?=
RMG-1	NXTkWYFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTJ6LkigxtEhOy54IH3nM2w>	Mnn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
FN-RMG-1	M3;ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;z[FJKSzVyPUSwMlUhyrFiND6yJI1oN0xMIN88US=>	MoDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
RMG-1-hFUT	NVe5enc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTV6LkGgxtEhOi52IH3nM2w>	NFTlO4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOlkyOyd-MkW3NlY6OTN:L3G+
FN-RMG-1-hFUT	M3jaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2XJ[2lEPTB;MUG4MlghyrFiMUOuPEBu\y:O	Mki3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5Mk[5NVMoRjJ3N{K2PVE{RC:jPh?=
CHP-134	NELjfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXwelEyKM7:TR?=		M37XZ2ROW00EoB?=	M2e5colvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>?	MnvRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUi0OlMoRjJ3NkW4OFY{RC:jPh?=
IMR-32	M1yycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDpVYQyKM7:TR?=		MkfpSG1UV8Li	NVjUO\|RkcW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OES2N{c,OjV4NUi0OlM9N2F-
CHP-134	MU\GeYN1cW:wIFHzd4F6	MYOxNEDPxE4EoB?=		NVvVSos2TE2VT9Mg	M1rRNIlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBIW0t{OEOwN\|cy	M{HpSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW4OFY{Lz5{NU[1PFQ3OzxxYU6=
IMR-32	M4XncmZ2[3Srb36gRZN{[Xl?	M3;EWlExKM7:TdMg		NEDUV25FVVORwrC=	NY\QcZJRcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N\|A{PzF?	NH;HVmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PFQ3Oyd-MkW2OVg1PjN:L3G+
A549	NVXUOWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHXV3kxNjJvNECwNEDPxE1?	NEHHXpI4OiCq		NGTkXYNKSzVyPUGyOkDDuSB3LkCg{txO	Mof6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4MkWyOFMoRjJ3NkK1NlQ{RC:jPh?=
A549/CDDP	Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\nTnNqOC5{LUSwNFAh\|ryP	M3zUVlczKGh?		M3m4S2lEPTB;MkSwxsDDucLiNEWuO{DPxE1?	M4XSXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1NlQ{Lz5{NU[yOVI1OzxxYU6=
H460	NWXoeXE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkWwNlQhcA>?	NHrKPYFFVVOR	MkXCTWM2OD15Lkmg{txO	NIjmPZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5PVk6PSd-MkW1PVk6QTV:L3G+
H460	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmi0O{46KM7:TR?=	MkLXNlQhcA>?	NFvz[oxFVVOR	MYfzbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV7OUm5OUc,OjV3OUm5PVU9N2F-
NRK-52E	MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWG3NuKhcMLi		MWjJR\|UxRTFyMDFCtUAyOi57IN88US=>	NWHXdnFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB\|PD;hQi=>
RGE	NEDYemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2jiSVczyqCqwrC=		MVfJR\|UxRTJ{INMxJFcvPCEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4NU[wN{c,OjV3NkW2NFM9N2F-
NRK-52E	M2jDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYC3NuKhcMLi		NX7OTW9jUUN6ME2xO\|khyrFiOT61JO69VQ>?	NWjXXXd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OlU3ODNpPkK1OVY2PjB\|PD;hQi=>
RGE	NUTrdYx{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkTPO\|LDqGkEoB?=		MYPJR\|gxRTZ\|INMxJFcvPCEQvF2=	Mn;mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NkW2NFMoRjJ3NU[1OlA{RC:jPh?=
SK-OV-3	M4jUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{DGdlczKGh?		M3ntbGlEPTB;MUC0Mlgh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
ES-2	M1vY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYm3NkBp		NHfoSYZKSzVyPUG0MlYh\|ryP	M3XFRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUKwNVMzLz5{NUWyNFE{OjxxYU6=
OVCAR-8	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEnM[pM4OiCq		NF\scIlKSzVyPUm2MlAh\|ryP	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
3AO	NEjRZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MW[3NkBp		NXjZXIN3UUN3ME22N{41KM7:TR?=	NFu5UJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyNFE{Oid-MkW1NlAyOzJ:L3G+
A2780	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUO3NkBp		MW\JR\|UxRTF2NT63JO69VQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{MEGzNkc,OjV3MkCxN\|I9N2F-
SW626	NUnwZ5BjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIXobIs4OiCq		MVfJR\|UxRTl5LkCg{txO	NXHBXXdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
OVCAR-3	MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mmf0O\|IhcA>?		M{LqXmlEPTB;M{KuOkDPxE1?	NX36VHl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NlAyOzJpPkK1OVIxOTN{PD;hQi=>
A549	NWG2b2c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHSzSJRKSzVyPUG1NU42PiEEsTC1N{4xPiEQvF2=	NX\pbotlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PjFpPkK1Nlc4PDZzPD;hQi=>
4T1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTh2Lk[yJOKyKDNyLkC1JO69VQpizszN	NELYZm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O\|Q3OSd-MkWyO\|c1PjF:L3G+
BALB/3T3	MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF[5d4VKSzVyPUG0MlMxKMLzIE[uOlgh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
B16	Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7XVFhNUUN3ME22OE4{OCEEsTC2MlgyKM7:TR?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
DU 145	M{fWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTN3LkC0JOKyKDF5LkW0JO69VQ>?	NWPrbpVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PjFpPkK1Nlc4PDZzPD;hQi=>
FaDu	M4\1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>?	M3vydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFYyLz5{NUK3O\|Q3OTxxYU6=
HCV-29T	MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUL4fXdrUUN3ME20PE42PyEEsTCyNk41QSEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S2NUc,OjV{N{e0OlE9N2F-
HL-60	M1rHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnwRpNKSzVyPUGxMlExKMLzIESuOFch\|ryP	NVTlbJR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|c1PjFpPkK1Nlc4PDZzPD;hQi=>
HT-29	NV3mNZFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTuTWM2OD16OT6xOkDDuSBzOD64OkDPxE1?	MoL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OlEoRjJ3Mke3OFYyRC:jPh?=
H146	NFm3XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTR7LkdCtVE{NjFizszN	NVq2WnZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
H187	NIHFVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXuTWM2OD1zMj63xtEzNjdizszN	NFHmZZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
H128	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;ob\|BmUUN3ME2xNFYvPMLzOT62JO69VQ>?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H69	NGLQblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTd4LkpCtVI4NjhizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H209	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfD[3NKSzVyPUK1PE4yyrF7OT64JO69VQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
DMS153	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjpWpJKSzVyPUW3MljDuTlwMjFOwG0>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{NEK4Nkc,OjVzMkSyPFI9N2F-
H526	NFHqfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fUe2lEPTB;Nz6yxtEyNjdizszN	NIPHUGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyOFI5Oid-MkWxNlQzQDJ:L3G+
DMS114	NU\YeXdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHwTXRKSzVyPUi1MljDuTF{Lkig{txO	NWLzcplyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlQzQDJpPkK1NVI1Ojh{PD;hQi=>
DMS53	M4LKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTF2Nj6yxtE{Pi52IN88US=>	Mn75QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkSyPFIoRjJ3MUK0NlgzRC:jPh?=
HeLa	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvT[FJvPS16MDFOwG0>			MkLsbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	M1\D[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC5N\|YxLz5{NUGwPVM3ODxxYU6=
MCF-7	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWG1MVgxKM7:TR?=			NEXm[pVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUO2NEc,OjVzMEmzOlA9N2F-
MDA-MB-231	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX:1MVgxKM7:TR?=			M1rQWYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk>	MoPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEmzOlAoRjJ3MUC5N\|YxRC:jPh?=
CaOV3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{jRRVczKGh?		MoLNTWM2OD16Nj6xJO69VQ>?	MoK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNki4OFkoRjJ3ME[4PFQ6RC:jPh?=
OVCAR-3	NEjaZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NY\ZPZRrPzJiaB?=		NXnnb4ZyUUN3ME2xO\|kvPSEQvF2=	M3\3RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
OVCAR-5	NX\lTIl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIL2d3o4OiCq		M37oXWlEPTB;N{WuO{DPxE1?	M1zWT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
SKOV-3	M4fNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWn3ZY5wPzJiaB?=		NFfRT2VKSzVyPUWwOEDPxE1?	M{m1S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
OVCAR-4	NGPlcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmPCO\|IhcA>?		NW\NXpZOUUN3ME2yPVAvPiEQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4OEi0PUc,OjVyNki4OFk9N2F-
OVCAR-8	MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mny1O\|IhcA>?		Mni5TWM2OD14OUCuNkDPxE1?	M1vub\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[4PFQ6Lz5{NUC2PFg1QTxxYU6=
MA148	M4GyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LWTFI1KGh?		NGXzN4hKSzVyPUizMlbjiIoEsfMAjVEvPCEQvHevcYw>	M2HGXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
A549	Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVy3OZJNOjRiaB?=		MlfoTWM2OD15N{[uNQKBkcLz4pEJNU46KM7:Zz;tcC=>	Mn71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
MDA-MB-231	NFHYRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH;vV5ozPCCq		M1ezTWlEPTB;N{S4MlDjiIoEsfMAjVEvOSEQvHevcYw>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|MUC5NUc,OjR6M{GwPVE9N2F-
NCI-ADR/RES	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{izUlI1KGh?		NIO3U5hKSzVyPUG3OVMvOOLCidMx5qCKPC52IN88[{9udA>?	NXnTfmhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|ExQTFpPkK0PFMyODlzPD;hQi=>
MA148	NInxNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mof5OFghcA>?		NHq0Z2pKSzVyPUK4MlHjiIoEsfMAjVEvOCEQvHevcYw>	M1;RT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
A549	NFPHfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWLocVZIPDhiaB?=		NHW0V5pKSzVyPUGxPE4x6oDLwsJihKkyNjJizsznM41t	M1fZWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MDA-MB-231	NY[wV5ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnfROFghcA>?		M{XTNGlEPTB;MUizMlDjiIoEsfMAjVEvOiBizsznM41t	M{nIeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
NCI-ADR/RES	NUC2SIZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFXYSog1QCCq		NWntU3RFUUN3ME2xPVMvOOLCidMx5qCKOS57IN88[{9udA>?	M1XmbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOxNFkyLz5{NEizNVA6OTxxYU6=
MA148	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV63NkBp		MV;JR\|UxRTF\|LkhihKnDueLCiUGuNkDPxGdxbXy=	Ml:yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
A549	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWO3NkBp		MWHJR\|UxRTZ2LkRihKnDueLCiUGuNUDPxGdxbXy=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh\|MUC5NUc,OjR6M{GwPVE9N2F-
MDA-MB-231	M3vLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3HrZ\|czKGh?		MXXJR\|UxRTl7LkZihKnDueLCiUGuNUDPxGdxbXy=	MojMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{GwPVEoRjJ2OEOxNFkyRC:jPh?=
NCI-ADR/RES	M1zOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGCw[mY4OiCq		M2j6SGlEPTB;M{euOQKBkcLz4pEJNU44KM7:Zz;tcC=>	NW\ibllRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|ExQTFpPkK0PFMyODlzPD;hQi=>
A549	M13Ee2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV[yWpJbPzJiaB?=	MXnEUXNQ	MkHXTWM2OD1zNUKuOFA6KM7:TR?=	M3S1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{KxN\|I{Lz5{NEeyNVMzOzxxYU6=
NCI-H157	MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1XJ[lczKGh?	NFy2[5VFVVOR	MW\JR\|UxRTh7Lkm3O{DPxE1?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{MUOyN{c,OjR5MkGzNlM9N2F-
PC9	MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXHPeZRKPzJiaB?=		NEPQdo5ISzVyPUexMlbDuTlwNTFCuW0>	NH7QdJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[xPFgxQSd-MkS2NVg5ODl:L3G+
A549	NH7jNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlTnO\|IhcA>?		NG\6PHZISzVyPUGzOuKyOzFwNjFCuW3DqA>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
PC9	NEHlN3lCeG:ydH;zbZMhSXO\|YYm=	NUPpU4p[OTByINM1US=>	MoXPO\|IhcA>?		Ml;WbY5lfWOnczDhdI9xfG:\|aYO=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZzOEiwPUc,OjR4MUi4NFk9N2F-
A549	NH:5WmJCeG:ydH;zbZMhSXO\|YYm=	M2DoblExOCEEtV2=	NGX2OlY4OiCq		NVvCSHBWcW6mdXPld{BieG:ydH;zbZM>	MlTnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MUi4NFkoRjJ2NkG4PFA6RC:jPh?=
A549	NYe3[nZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NELkNZQzPCCq		M2fCc2lEOTB;MT60O\|Yhdk1?	NYfBbmJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPVY1OzdpPkK0N\|k3PDN5PD;hQi=>
H1299	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYDabWtsOjRiaB?=		NF7HTmxKSzFyPUCuOFQ{KG6P	MkPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|OU[0N\|coRjJ2M{m2OFM4RC:jPh?=
HCC15	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnOzNlQhcA>?		M1fiSGlEOTB;MD6zOFYhdk1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7NkSzO{c,OjR\|OU[0N\|c9N2F-
H157	M2H4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXmyOEBp		Mn;kTWMyOD1yLkixJI5O	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN7NkSzO{c,OjR\|OU[0N\|c9N2F-
A2780	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvFSplKSzVyPUG0MlDjiIoEsfMAjVEvPCEQvF2=	M1;iUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkC5Olk{Lz5{NEKwPVY6OzxxYU6=
A2780cisR	M4ewNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTldWlmUUN3ME20PE466oDLwsJihKk{NjlizszN	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJyOU[5N{c,OjR{MEm2PVM9N2F-
A2780ZD0473R	MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rzS2lEPTB;NkSuOwKBkcLz4pEJN{4zKM7:TR?=	NYfD[ZdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNFk3QTNpPkK0NlA6Pjl\|PD;hQi=>
SKOV-3	NXTCVYRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonyTWM2OD12Mz605qCKyrIkgJmzMlkh\|ryP	NY\xR4R2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyNFk3QTNpPkK0NlA6Pjl\|PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pChK-2 / Chk-2 ; PubMed: 30049957 Int J Mol Sci Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; PubMed: 30049957 Int J Mol Sci Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ p-p38 / p38 / Cleaved PARP / PARP ; PubMed: 30049957 Int J Mol Sci A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋𢡄�෋䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemｾ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒ｾ᎒�堞ﻮ᎒፲露𢡄	30049957
Immunofluorescence	γH2AX ; PubMed: 24348048 Onco Targets Ther Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ	24348048
Growth inhibition assay	Cell viability ; PubMed: 24348048 Onco Targets Ther SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay.	24348048

In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. ^[1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. ^[3]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: A2780, SKOV3, IGROV-1 and HX62
Concentrations: 0-200 μM
Incubation Time: 72 hours
Method:
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
Administration: Administered via i.p.
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	14 mg/mL warmed (37.71 mM)
	DMSO	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Carboplatin (NSC 241240) SDF

Molecular Weight	371.25
Formula	C₆H₁₂N₂O₄Pt
CAS No.	41575-94-4
Storage	2 years 4°C(in the dark) powder
Synonyms	JM-8, CBDCA
Smiles	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04907968	Recruiting	Drug: XMT-1536 (Upifitamab Rilsodotin)\|Drug: Carboplatin	Platinum-sensitive Ovarian Cancer (UPGRADE-A)	Mersana Therapeutics\|IQVIA Biotech	June 11 2021	Phase 1\|Phase 2
NCT04606914	Recruiting	Drug: mirvetuximab soravtansine (MIRV; IMGN853)	Ovarian Cancer\|Fallopian Tube\|Primary Peritoneal Cancer	University of Alabama at Birmingham	May 27 2021	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you advise what solvent to use and the concentration for S1215 for in vitro use?
Answer:
DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Choose Your Country or Region

By Signaling Pathways

By product type

Carboplatin (NSC 241240)